Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON42675
NL-OMON42675
Completed
Not Applicable

Prostate Cancer Molecular Medicine: Transition Grant 2015 (ProCaMolMed) - ProCaMolMed

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites525 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
525
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Retrospective cohort
  • •\- Participants of Group 1 and/or 2 in PCMM.
  • •\- Obtained informed consent in PCMM.;Prospective cohort
  • •\- Men \>\= 18 years.
  • •\- Planned to undergo prostate biopsies according to standard practice.
  • •\- Signed informed consent.

Exclusion Criteria

  • •Prospective cohort
  • •\- Documented acute prostatitis or urinary tract infections within 8 weeks prior to inclusion.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Prostate Cancer Molecular MedicineProstate cancerprostate carcinoma1003859710036958
NL-OMON39774Erasmus MC, Universitair Medisch Centrum Rotterdam496
Recruiting
Not Applicable
Prostate Cancer Molecular Medicine (PCMM).Prostate cancer / prostaatkanker
NL-OMON27495Erasmus MC, NKI-AvL, UMCG, UMC400
Active, not recruiting
Phase 1
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Metastatic prostate cancerTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2022-003788-13-FIHeikki Minn40
Active, not recruiting
Phase 1
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Prostate cancerTherapeutic area: Diseases [C] - Male Urogenital Diseases [C12]
CTIS2024-511104-16-00Turku University Hospital40
Completed
Not Applicable
Transmurale zorg Prostaatkanker, van diagnose tot en met nazorgProstate cancer, transmural care, decision aid, SDM, Follow-up care, Substitution, Family doctors or General practitioners, Prostaatkanker, Keuzehulp, Samenwerking tussen eerste lijn en tweede lijn.
NL-OMON22953Initiator: Catharina Wilhelmina Hospital (CWZ)NijmegenPrimary Sponsor/Performer: Radboud University Nijmegen Medical centerOther performers: CWZ in Nijmegen, Maashospital Pantein in Boxmeer200